Wall Street: GLP-1 competitors’ pain is Eli Lilly’s gain

Eli Lilly’s stock continued its wild ride Wednesday after lackluster data from Amgen’s potential GLP-1 competitor further demonstrated tirzepatide’s advantage.

On Wednesday, Lilly shares $LLY spiked nearly 5% before closing at $725.38, still a 3% increase for the day. Those gains were…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks